Cingulate Inc. (NASDAQ:CINGW) Short Interest Update

Cingulate Inc. (NASDAQ:CINGWGet Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totaling 402 shares, a decline of 96.3% from the May 31st total of 10,882 shares. Based on an average daily volume of 13,143 shares, the days-to-cover ratio is presently 0.0 days.

Cingulate Stock Performance

Shares of Cingulate stock traded down $0.00 during trading hours on Friday, reaching $0.02. The stock had a trading volume of 843 shares, compared to its average volume of 38,754. Cingulate has a 1 year low of $0.02 and a 1 year high of $0.17. The firm has a 50 day simple moving average of $0.02 and a two-hundred day simple moving average of $0.05.

About Cingulate

(Get Free Report)

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

Further Reading

Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.